- Home
- CWT vs CELC Comparison
CWT vs CELC Comparison
Compare CWT & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWT
- CELC
- Stock Information
- Founded
- CWT 1926
- CELC 2011
- Country
- CWT United States
- CELC United States
- Employees
- CWT N/A
- CELC N/A
- Industry
- CWT Water Supply
- CELC Medical Specialities
- Sector
- CWT Utilities
- CELC Health Care
- Exchange
- CWT Nasdaq
- CELC Nasdaq
- Market Cap
- CWT 2.8B
- CELC 2.8B
- IPO Year
- CWT N/A
- CELC 2017
- Fundamental
- Price
- CWT $49.36
- CELC $74.44
- Analyst Decision
- CWT Strong Buy
- CELC Strong Buy
- Analyst Count
- CWT 2
- CELC 5
- Target Price
- CWT $54.50
- CELC $69.40
- AVG Volume (30 Days)
- CWT 363.5K
- CELC 1.6M
- Earning Date
- CWT 10-30-2025
- CELC 11-13-2025
- Dividend Yield
- CWT 2.43%
- CELC N/A
- EPS Growth
- CWT N/A
- CELC N/A
- EPS
- CWT 2.28
- CELC N/A
- Revenue
- CWT $990,685,000.00
- CELC N/A
- Revenue This Year
- CWT N/A
- CELC N/A
- Revenue Next Year
- CWT $6.23
- CELC N/A
- P/E Ratio
- CWT $21.61
- CELC N/A
- Revenue Growth
- CWT 0.63
- CELC N/A
- 52 Week Low
- CWT $41.64
- CELC $7.58
- 52 Week High
- CWT $52.83
- CELC $83.00
- Technical
- Relative Strength Index (RSI)
- CWT 64.71
- CELC 70.36
- Support Level
- CWT $49.06
- CELC $64.61
- Resistance Level
- CWT $50.44
- CELC $80.13
- Average True Range (ATR)
- CWT 1.08
- CELC 5.00
- MACD
- CWT 0.20
- CELC 2.42
- Stochastic Oscillator
- CWT 75.62
- CELC 77.38
About CWT California Water Service Group
California Water Service Group is a U.S. water and utilities holding company based in California. The company engages in the production, treatment, storage, distribution, and sale of water for various uses. The firm operates through its subsidiaries, which can be divided between regulated and unregulated businesses. The regulated public utilities subsidiaries operate in California, New Mexico, Washington, and Hawaii. The unregulated subsidiaries provide water utility services to private companies and municipalities. The company derives the majority of its revenue from its operations in California and, overall, from residential customers.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.